Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tramadol · Rybix Odt, Ultram

Small molecule · Agonist · developed by Janssen Pharms

Approved FDA, Mar 1995
3 Registered trials

What is Tramadol?

Tramadol is a synthetic codeine analogue with central analgesic activity, acting on opioid receptors and weakly inhibiting norepinephrine and serotonin reuptake. It is studied in severe and acute pain, including postoperative pain, and in patients with thyroid and parathyroid conditions and anterior cruciate ligament tear.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Rybix Odt, Ultram, Ultram Er
Drug type
Small molecule
Mechanism
Agonist
Pathways
opioid receptor signaling, norepinephrine reuptake, serotonin reuptake
Therapy area
Oncology
Developer
Janssen Pharms
In trials of
NERV, PCRX, VTRS
FDA status
Approved as Rybix Odt, Ultram, Ultram Er (March 3, 1995), NDA020281
UNII
0NG5TTM63P

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03469310 Phase 4 Thyroid Cancer Completed NERV
NCT06215859 Phase 3 Acute Pain Completed VTRS
NCT06340932 N/A ACL Tear Completed PCRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ACL TearAcute PainPainParathyroid AdenomaParathyroid DiseasesParathyroid HyperplasiaPost Operative PainThyroid CancerThyroid DiseasesThyroid GoitreThyroid NeoplasmsThyroid Nodule

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.